- Home
- CRVS vs BNY Comparison
CRVS vs BNY Comparison
Compare CRVS & BNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- BNY
- Stock Information
- Founded
- CRVS 2014
- BNY 2001
- Country
- CRVS United States
- BNY United States
- Employees
- CRVS N/A
- BNY N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- BNY Trusts Except Educational Religious and Charitable
- Sector
- CRVS Health Care
- BNY Finance
- Exchange
- CRVS Nasdaq
- BNY Nasdaq
- Market Cap
- CRVS 257.0M
- BNY 249.4M
- IPO Year
- CRVS 2016
- BNY N/A
- Fundamental
- Price
- CRVS $2.99
- BNY $10.30
- Analyst Decision
- CRVS Strong Buy
- BNY
- Analyst Count
- CRVS 5
- BNY 0
- Target Price
- CRVS $12.63
- BNY N/A
- AVG Volume (30 Days)
- CRVS 715.8K
- BNY 52.7K
- Earning Date
- CRVS 05-05-2025
- BNY 01-01-0001
- Dividend Yield
- CRVS N/A
- BNY 3.93%
- EPS Growth
- CRVS N/A
- BNY N/A
- EPS
- CRVS N/A
- BNY N/A
- Revenue
- CRVS N/A
- BNY N/A
- Revenue This Year
- CRVS N/A
- BNY N/A
- Revenue Next Year
- CRVS N/A
- BNY N/A
- P/E Ratio
- CRVS N/A
- BNY N/A
- Revenue Growth
- CRVS N/A
- BNY N/A
- 52 Week Low
- CRVS $1.30
- BNY $8.60
- 52 Week High
- CRVS $10.00
- BNY $10.80
- Technical
- Relative Strength Index (RSI)
- CRVS 26.38
- BNY 50.24
- Support Level
- CRVS $3.06
- BNY $10.17
- Resistance Level
- CRVS $3.31
- BNY $10.39
- Average True Range (ATR)
- CRVS 0.36
- BNY 0.10
- MACD
- CRVS -0.10
- BNY 0.01
- Stochastic Oscillator
- CRVS 1.11
- BNY 72.06
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr has an investment objective to provide current income exempt from regular U.S. federal income tax and New York State and New York City personal income taxes. The Trust seeks to achieve its investment objective by investing primarily in municipal bonds exempt from U.S. federal income taxes and New York State and New York City personal income taxes.